Article PDF
References
Nagi DK, Hendra TJ, Ryle AJ, Cooper TM, Temple RC, Clark PMS, Schneider AE, Hales CN, Yudkin JS (1990) The relationships of concentrations of insulin, intact proinsulin and 32–33 split proinsulin with cardiovascular risk factors in Type 2 (non-insulin-dependent) diabetic subjects. Diabetologia 33: 532–537
Sobey WJ, Beer SF, Carrington CA, Clark PMS, Frank BH, Gray IP, Luzio SD, Owens DR, Schneider AE, Siddle K, Temple RC, Hales CN (1989) Sensitive and specific two-site immunoradiometric assays for human insulin, proinsulin, 65–66 split and 32–33 split proinsulins. Biochem J 260: 535–541
Temple RC, Clark PMS, Nagi DK, Schneider AE, Yudkin JS, Hales CN (1990) Radioimmunoassay may overestimate insulin in non-insulin-dependent diabetics. Clin Endocrinol 32: 689–693
Steiner DF, Kemmler W, Tager HS, Peterson JD (1974) Proteolytic processing in the biosynthesis of insulin and other proteins. Fed Proc 33: 2105–2115
Orci L, Ravazzola M, Storch M-J, Anderson RGW, Vassalli J-D, Perrelet A (1987) Proteolytic maturation of insulin is a post-Golgi event which occurs in acidifying clathrin-coated secretory vesicles. Cell 49: 865–868
Davidson HW, Hutton JC (1987) The insulin-secretory-granule carboxypeptidase H. Purification and demonstration of involvement in proinsulin processing. Biochem J 245: 575–582
Davidson HW, Rhodes CJ, Hutton JC (1988) Intraorganellar calcium and pH control proinsulin cleavage in the pancreatic β cell via two distinct site-specific endopeptidases. Nature 333: 93–96
Given BD, Cohen RM, Schoelson SE, Frank BH, Rubenstein AH, Tager HS (1985) Biochemical and clinical implications of proinsulin conversion intermediates. J Clin Invest 76: 1398–1405
Peavy DE, Brunner MR, Duckworth WC, Hooker CS, Frank BH (1985) Receptor binding and biological potency of several split forms (conversion intermediates) of human proinsulin. J Biol Chem 260: 13989–13994
Gross DJ, Villa-Komaroff L, Kahn CR, Weir GC, Halban PA (1989) Deletion of a highly conserved tetrapeptide sequence of the proinsulin connecting peptide (C-peptide) inhibits proinsulin to insulin conversion by transfected pituitary corticotroph (AtT20) cells. J Biol Chem 264: 21486–21490
Docherty K, Rhodes CJ, Taylor NA, Shennan KIJ, Hutton JC (1989) Proinsulin endopeptidase substrate specificities defined by site-directed mutagenesis of proinsulin. J Biol Chem 264: 18335–18339
Ward WK, LaCava EC, Paquette TL, Beard JC, Wallum BJ, Porte Jr D (1987) Disproportionate elevation of immunoreactive proinsulin in Type 2 (non-insulin-dependent) diabetes mellitus and in experimental insulin resistance. Diabetologia 30: 698–702
Yoshioka N, Kuzuya T, Matsuda A, Taniguchi M, Iwamoto Y (1988) Serum proinsulin levels at fasting and after oral glucose load in patients with Type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 31: 355–360
Heaton DA, Millward BA, Gray IP, Tun Y, Hales CN, Pyke DA, Leslie RDG (1988) Increased proinsulin levels as an early indicator of B-cell dysfunction in non-diabetic twins of Type 1 (insulin-dependent) diabetic patients. Diabetologia 31: 182–184
Porte Jr D, Kahn SE (1989) Hyperproinsulinemia and amyloid in NIDDM. Clues to etiology of islet β-cell dysfunction? Diabetes 38: 1333–1336
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Halban, P.A. Proinsulin conversion intermediates: a possible source of confusion. Diabetologia 34, 202–203 (1991). https://doi.org/10.1007/BF00418280
Issue Date:
DOI: https://doi.org/10.1007/BF00418280